[go: up one dir, main page]

PE20180464A1 - HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA - Google Patents

HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA

Info

Publication number
PE20180464A1
PE20180464A1 PE2018000088A PE2018000088A PE20180464A1 PE 20180464 A1 PE20180464 A1 PE 20180464A1 PE 2018000088 A PE2018000088 A PE 2018000088A PE 2018000088 A PE2018000088 A PE 2018000088A PE 20180464 A1 PE20180464 A1 PE 20180464A1
Authority
PE
Peru
Prior art keywords
pyrimidin
trifluoromethyl
bis
amino
oxobutil
Prior art date
Application number
PE2018000088A
Other languages
English (en)
Inventor
Ki Sook Park
Jung Min Yun
Bong Chan Kim
Kyu Young Kim
Ji Hye Lee
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20180464A1 publication Critical patent/PE20180464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Referido a un 1,5 hidrato de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidro-pirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona, el cual tiene un contenido de agua en el rango que oscila entre 3,5% y 5,5%, los valores caracteristicos del pico (2 theta) en el difractograma de XRD son de 14.7766°, 15.4912°, 17.835°, 20.036°, 21.322° y 22.694°. Tambien se refiere a un proceso para prepararlo y a una composicion farmaceutica que lo comprende. Dicho compuesto es un inhibidor de la dipeptidil peptidasa-IV (DPP-IV), siendo util para el tratamiento de la diabetes
PE2018000088A 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA PE20180464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01

Publications (1)

Publication Number Publication Date
PE20180464A1 true PE20180464A1 (es) 2018-03-06

Family

ID=45995015

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018000088A PE20180464A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2013000904A PE20140392A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2023001454A PE20240220A1 (es) 2010-11-01 2011-10-31 SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2013000904A PE20140392A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2023001454A PE20240220A1 (es) 2010-11-01 2011-10-31 SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO

Country Status (29)

Country Link
US (1) US8859567B2 (es)
EP (1) EP2635580B1 (es)
JP (1) JP6193762B2 (es)
KR (1) KR101446789B1 (es)
CN (1) CN103189375B (es)
AP (1) AP3287A (es)
AR (1) AR083591A1 (es)
AU (1) AU2011324253B2 (es)
BR (1) BR112013010586A2 (es)
CA (1) CA2814357C (es)
CL (1) CL2013001137A1 (es)
CO (1) CO6710945A2 (es)
DO (1) DOP2013000090A (es)
EA (1) EA024679B1 (es)
EC (1) ECSP13012599A (es)
GE (1) GEP20156218B (es)
IL (1) IL225808A (es)
MA (1) MA34625B1 (es)
MX (1) MX341584B (es)
MY (1) MY156428A (es)
NZ (1) NZ609644A (es)
PE (3) PE20180464A1 (es)
PH (1) PH12013500685A1 (es)
SG (1) SG189931A1 (es)
TW (1) TWI519533B (es)
UA (1) UA106445C2 (es)
UY (1) UY33696A (es)
WO (1) WO2012060590A2 (es)
ZA (1) ZA201302646B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2007752T1 (sl) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
SG11201507117XA (en) 2013-03-06 2015-10-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
PH12023550900A1 (en) * 2020-10-13 2024-03-04 Lg Chemical Ltd Oral combined formulation including gemigliptin and dapagliflozin and preparation method therefor
KR20250137744A (ko) 2024-03-11 2025-09-19 엠에프씨 주식회사 제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko) 2024-03-27 2025-10-14 엠에프씨 주식회사 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
CN119285630B (zh) * 2024-09-05 2025-05-27 安徽峆一药业股份有限公司 一种吉格列汀草酸盐及其晶型、制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1554256B1 (en) * 2002-07-15 2009-12-09 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2006516573A (ja) * 2003-01-31 2006-07-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
AR083591A1 (es) 2013-03-06
ZA201302646B (en) 2014-01-29
JP2013540810A (ja) 2013-11-07
TW201245189A (en) 2012-11-16
NZ609644A (en) 2016-02-26
PH12013500685A1 (en) 2015-10-02
AU2011324253A1 (en) 2013-05-02
MX341584B (es) 2016-08-25
GEP20156218B (en) 2015-01-12
EP2635580B1 (en) 2015-08-12
UY33696A (es) 2012-04-30
KR20120046069A (ko) 2012-05-09
PE20140392A1 (es) 2014-03-22
EA201390644A1 (ru) 2014-11-28
CA2814357A1 (en) 2012-05-10
WO2012060590A3 (en) 2012-06-28
AU2011324253B2 (en) 2015-10-29
TWI519533B (zh) 2016-02-01
US20130203787A1 (en) 2013-08-08
CN103189375B (zh) 2016-08-10
IL225808A (en) 2016-08-31
KR101446789B1 (ko) 2014-10-01
JP6193762B2 (ja) 2017-09-06
AP3287A (en) 2015-05-31
MY156428A (en) 2016-02-26
IL225808A0 (en) 2013-06-27
MX2013004776A (es) 2013-11-04
CN103189375A (zh) 2013-07-03
EP2635580A2 (en) 2013-09-11
SG189931A1 (en) 2013-06-28
US8859567B2 (en) 2014-10-14
CO6710945A2 (es) 2013-07-15
ECSP13012599A (es) 2013-07-31
PE20240220A1 (es) 2024-02-16
MA34625B1 (fr) 2013-10-02
CL2013001137A1 (es) 2013-09-06
DOP2013000090A (es) 2018-06-30
EP2635580A4 (en) 2014-04-02
EA024679B1 (ru) 2016-10-31
BR112013010586A2 (pt) 2016-08-09
AP2013006866A0 (en) 2013-05-31
WO2012060590A2 (en) 2012-05-10
UA106445C2 (ru) 2014-08-26
CA2814357C (en) 2015-07-07

Similar Documents

Publication Publication Date Title
PE20180464A1 (es) HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CL2012001250A1 (es) Compuestos derivados de espirooxoindol, antagonista de la interaccion entre p53 y mdm2; composición farmacéutica que lo comprende; a un kit farmacéutico; uso en el tratamiento del cancer.
PE20140864A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
CL2011002930A1 (es) Compuestos derivados de 8-oxo-9-[3-(1h-bencimidazol-2-iloxi)-fenil]-4,5,6,7,8,9-hexahidro-2h-pirrolo[3,4-b]quinolina-3-carboxilato de etilo; procedimiento de preparacion; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso del compuesto como inhibidor selectivo de quinasas aurora a y b para tratar el cancer.
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2018001324A (es) Forma cristalina de base libre de lorlatinib.
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
SV2011003973A (es) Estimuladores de la sgc o activadores de la sgc en combinacion con inhibidores de la pde5 para el tratamiento de la disfuncion erectil
PH12013500942A1 (en) Triazolopyridine compounds
CL2012001322A1 (es) Compuestos derivados de piridinopiridinona, inhibidores pdgf; procedimiento de preparacion de estos; composición farmacéutica que los comprende; combinación farmacéutica; y su uso en el tratamiento del cancer, ateroesclerosis, enfermedades cardiacas, diabetes, renales, entre otras.
CL2012003011A1 (es) Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa.
PE20170469A1 (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo
CL2013000434A1 (es) Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia.
TN2013000161A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
MX354999B (es) Composicion con un inhibidor de la bomba de protones y un antagonista h2.
CL2013000931A1 (es) Polimorfos b y c de picropodofilina; metodos para su preparacion; composicion farmaceutica que los comprende; kit farmaceutico; y su uso para el tratamiento del cancer, tal como cancer de pulmon, de mama y gastrointestinal, psoriasis, diabetes mellitus tipo 2, entre otras enfermedades.
CL2011001401A1 (es) Compuesto derivado de morfina-6-glucuronido; composicion farmaceutica que lo comprende; uso del compuesto en el tratamiento o prevencion del dolor.